Related Experiment Video
Updated: May 30, 2025
Real-time Cytotoxicity Assays in Human Whole Blood
Published on: November 7, 2014
Updates in atypical hemolytic syndrome
Keri Drake1, Jyothsna Gattineni
1Division of Pediatric Nephrology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Purpose Of Review:
This review aims to summarize how scientific advances in complement biology have not only improved the diagnosis and management of aHUS but also continue to offer insights into the pathophysiology of complement-mediated disease that may be leveraged for future therapeutic developments.
Recent Findings:
Updated information on the clinical and epidemiological features, pathophysiology, diagnosis, management, and potential for future therapeutic advancements in the treatment of aHUS are reviewed.
Summary:
aHUS is a rare but potentially life-threatening disease that requires prompt diagnosis and treatment as well as long-term management via a multidisciplinary team providing coordination of primary and specialty care as well as outreach and education for children and families affected by this life-long disease.
More Related Videos
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Related Concept Videos
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
02:20Blood Types
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...